BMS-833923

• CAT Number: I000303
• CAS Number: 1059734-66-5
• Molecular Formula: C₃₀H₂₇N₅O
• Molecular Weight: 473.57
• Purity: ≥95%
• Synonyms: N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide
• Target: Smoothened
• Solubility: in DMSO > 10 mM
• Storage: Store at -20°C
• IC50: 6-35 nM [1]
• InChI: InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)
• InChIKey: KLRRGBHZCJLIEL-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)CNC)NC(=O)C2=CC=C(C=C2)NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5

BMS-833923 (Cat.No:I000303) is a potent and selective inhibitor of transforming growth factor-beta receptor type I (TGF-βRI) kinase. It has shown antitumor activity in preclinical models of various cancer types, including breast, prostate, and lung cancer. BMS-833923 has also demonstrated potential as a treatment for fibrotic diseases such as pulmonary fibrosis and liver fibrosis. Clinical trials evaluating its safety and efficacy are ongoing.

Reference

[1]. Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1.